Acrivastine

Chemical formula: C₂₂H₂₄N₂O₂  Molecular mass: 348.438 g/mol  PubChem compound: 5284514

Active ingredient description

Acrivastine, a structural analog of triprolidine hydrochloride, exhibits H1-antihistaminic activity in isolated tissues, animals, and humans, and has sedative effects in humans. The propionic acid derivative of acrivastine is a metabolite in several animal species (as well as in man) and also exhibits H1-antihistaminic activity.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
R06AX18 Acrivastine R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX18

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
SEMPREX D Capsule FDA, National Drug Code (US) MPI, US: SPL/Old

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 87848-99-5
DrugBank Drug: DB09488
KEGG Drug: D02760
PubChem Compound: 5284514
RxNorm Ingredient: 19959
SNOMED-CT Concept: 391716003
Acrivastine (substance)
UNII Identifier: A20F9XAI7W
ACRIVASTINE

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.